Talabostat

DB06182InvestigationalSmall molecule

Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), lung cancer, melanoma, and pancreatic cancer.

Chemical structure of Talabostat
Primary indication
Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), lung cancer, melanoma, and pancreatic cancer.Curator reviewed
Formula / weight
C9H19BN2O3 · 214.07 g/mol (avg)
Code names
BXCL701 · PT-100

Resolves to

Compound
UNIIKZ1O2SH88ZCAS149682-77-9ChEMBLCHEMBL67279
Structure
InChIKeyFKCMADOPPWWGNZ-YUMQZZPRSA-NSMILESCC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O
Targets
Q86TI2DPP9Q6V1X1DPP8Q12884FAP

What you can answer from here — as of September 21, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
13Clinical trialsPhase, status and sponsor resolved per trial
Sign in
9+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Talabostat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In